Limited Announces Closing of Public Offering and Nasdaq Listing
Summary
London, May 19, 2022 OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (OKYO Pharma or the Company), a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announced the closing of its underwritten public offering of 625,000 American Depository Shares (the ADSs) at a public offering price of $4.00 per share, for gross proceeds of $2.5 million, before deducting underwriting discounts and offering expenses.OKYO intends to use the net proceeds from this Offering: (i) to advance OK-101 to the filing of an IND to treat DED; (ii) to fund the initial Phase 2 clinical trial of OK-101 in DED patients; and (iii) for working capital and other general corporate purposes.ThinkEquity acted as sole book-running manager for the offering.A registration statement on Form F-1 (File No. Copies of the final prospectus may be obtained from ThinkEquity, 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, by email at prospectus@think-equity.com.This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) is a life sciences company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain. OKYOs therapeutic approach is focused on targeting inflammatory and pain modulation pathways that drive these conditions. The Company is presently developing OK-101, its lead preclinical product candidate, for the treatment of dry-eye disease DED. These forward-looking statements are not historical facts but rather are based on the Companys current expectations, estimates, and projections about its industry; its beliefs; and assumptions.